BACKGROUND: Children with tularemia are, irrespective of severity of disease, usually subjected to parenteral treatment with aminoglycosides. Based on available susceptibility testing, quinolones might be effective oral alternatives of parenteral therapy. These drugs cause arthropathy in immature animals, but this risk is currently regarded to be low in humans. PATIENTS AND METHODS: In 12 patients (median age, 4 years; range, 1 to 10) with ulceroglandular tularemia, a 10- to 14-day course of oral ciprofloxacin, 15 to 20 mg/kg daily in 2 divided doses, was prescribed. Microbiologic investigations included identification of the infectious agent by PCR and culture of wound specimens, as well as determination of antibiotic susceptibility of isolates of Francisella tularensis. RESULTS: Defervescence occurred within 4 days of institution of oral ciprofloxacin in all patients. After a median period of 4.5 days (range, 2 to 24), the patients were capable of outdoor activities. In 2 cases, treatment was withdrawn after 3 and 7 days because of rash. In both cases a second episode of fever occurred. All children recovered without complications. In 7 cases F. tularensis was successfully cultured from ulcer specimens and tested for susceptibility to ciprofloxacin. MIC values for all isolates were 0.03 mg/l. CONCLUSION: In our sample of 12 patients ciprofloxacin was satisfactory for outpatient treatment of tularemia in children.
BACKGROUND:Children with tularemia are, irrespective of severity of disease, usually subjected to parenteral treatment with aminoglycosides. Based on available susceptibility testing, quinolones might be effective oral alternatives of parenteral therapy. These drugs cause arthropathy in immature animals, but this risk is currently regarded to be low in humans. PATIENTS AND METHODS: In 12 patients (median age, 4 years; range, 1 to 10) with ulceroglandular tularemia, a 10- to 14-day course of oral ciprofloxacin, 15 to 20 mg/kg daily in 2 divided doses, was prescribed. Microbiologic investigations included identification of the infectious agent by PCR and culture of wound specimens, as well as determination of antibiotic susceptibility of isolates of Francisella tularensis. RESULTS: Defervescence occurred within 4 days of institution of oral ciprofloxacin in all patients. After a median period of 4.5 days (range, 2 to 24), the patients were capable of outdoor activities. In 2 cases, treatment was withdrawn after 3 and 7 days because of rash. In both cases a second episode of fever occurred. All children recovered without complications. In 7 cases F. tularensis was successfully cultured from ulcer specimens and tested for susceptibility to ciprofloxacin. MIC values for all isolates were 0.03 mg/l. CONCLUSION: In our sample of 12 patientsciprofloxacin was satisfactory for outpatient treatment of tularemia in children.
Authors: Michael A Pammit; Varija N Budhavarapu; Erin K Raulie; Karl E Klose; Judy M Teale; Bernard P Arulanandam Journal: Antimicrob Agents Chemother Date: 2004-12 Impact factor: 5.191
Authors: Fang-Yi Su; Selvi Srinivasan; Brian Lee; Jasmin Chen; Anthony J Convertine; Timothy Eoin West; Daniel M Ratner; Shawn J Skerrett; Patrick S Stayton Journal: J Control Release Date: 2018-08-09 Impact factor: 9.776
Authors: Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner Journal: Biomaterials Date: 2018-10-16 Impact factor: 12.479
Authors: Kerstin Svensson; Andreas Sjödin; Mona Byström; Malin Granberg; Mitchell J Brittnacher; Laurence Rohmer; Michael A Jacobs; Elizabeth H Sims-Day; Ruth Levy; Yang Zhou; Hillary S Hayden; Regina Lim; Jean Chang; Donald Guenthener; Allison Kang; Eric Haugen; Will Gillett; Rajinder Kaul; Mats Forsman; Pär Larsson; Anders Johansson Journal: J Bacteriol Date: 2012-12 Impact factor: 3.490
Authors: Charlotte A Hall; Helen C Flick-Smith; Sarah V Harding; Helen S Atkins; Richard W Titball Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191